Patrick Flamen, MD, PhD, is since 2003 the head of the Nuclear Medicine Imaging and Radionuclide Therapy department of the Jules Bordet Institute, a dedicated comprehensive university cancer institute located in the heart of Brussels, and associated to the Université Libre de Bruxelles (ULB). In 2018 his department performed more than 3500 SPECT-CT and 6000 PET-CT studies, and about 225 radiomolecular treatments. The available diagnostic systems include a PET-CT and 2 SPECT-CT cameras.

Patrick Flamen graduated at the Medical School of the University of Ghent, Belgium, in 1990. He specialised in Nuclear Medicine at the Vrije Universiteit van Brussel (VUB) in Brussels, Belgium. Thereafter, he worked for 5 years in the University Hospital of Leuven, Belgium, where he obtained a PhD degree in Biomedical Sciences in May 2001 on the use of FDG PET in Digestive Oncology. He presently has an academic appointment at the Université Libre de Bruxelles (ULB).

His research activities mainly focus on the use of positron emission tomography (PET-CT) for Molecular Imaging in clinical and translational research in oncology. He is involved in multiple academy and industry driven trials on the development and validation of molecular imaging biomarkers for assessing and predicting cancer treatment efficacy and patient outcome. He is also the driving force of the development of new targeted radionuclide treatments (radioembolization of liver tumours using Y90-labeled microspheres; radioimmunotherapy of CD20-positive lymphoma with Y90-rituximab; Radium-223 for bone metastasis; Lutetium-177 octreotate for neuroendocrine tumours and Lu177-PSMA ligand therapy for prostate cancer).

He is the (co)author of 115 peer reviewed scientific articles and three book chapters.